Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i>

• Автори: Worapong Nasomsong (Автор), Parnrada Nulsopapon (Автор), Dhitiwat Changpradub (Автор), Supanun Pungcharoenkijkul (Автор), Patomroek Hanyanunt (Автор), Tassanawan Chatreewattanakul (Автор), Wichai Santimaleeworagun (Автор)
• Формат: Книга
• Опубліковано: MDPI AG, 2022-04-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Carbapenem-resistant <i>Pseudomonas aeruginosa</i> (CRPA) is a hospital-acquired pathogen with a high mortality rate and limited treatment options. We investigated the activity of ceftolozane/tazobactam (C/T) and its synergistic effects with amikacin to extend the range of optimal therap...